The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease.

As part of this approval, Regeneron Pharmaceuticals successfully redeemed its Priority Review Voucher, a move aimed at accelerating the review process for innovative therapies. This approval marks an important step forward for Eylea Hd in the field of rare pediatric disease treatment. The redemption of the Priority Review Voucher further highlights the potential of this therapy to address unmet medical needs, bringing new hope to the relevant patient population.